• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有尖峰表达的基因在染色体(亚)带中聚集,并且尖峰(亚)带在多发性骨髓瘤患者中有很强的预后价值。

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.

机构信息

INSERM U1040, Montpellier, France.

出版信息

Haematologica. 2012 Apr;97(4):622-30. doi: 10.3324/haematol.2011.046821. Epub 2011 Nov 18.

DOI:10.3324/haematol.2011.046821
PMID:22102711
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3347668/
Abstract

BACKGROUND

Genetic abnormalities are common in patients with multiple myeloma, and may deregulate gene products involved in tumor survival, proliferation, metabolism and drug resistance. In particular, translocations may result in a high expression of targeted genes (termed spike expression) in tumor cells. We identified spike genes in multiple myeloma cells of patients with newly-diagnosed myeloma and investigated their prognostic value.

DESIGN AND METHODS

Genes with a spike expression in multiple myeloma cells were picked up using box plot probe set signal distribution and two selection filters.

RESULTS

In a cohort of 206 newly diagnosed patients with multiple myeloma, 2587 genes/expressed sequence tags with a spike expression were identified. Some spike genes were associated with some transcription factors such as MAF or MMSET and with known recurrent translocations as expected. Spike genes were not associated with increased DNA copy number and for a majority of them, involved unknown mechanisms. Of spiked genes, 36.7% clustered significantly in 149 out of 862 documented chromosome (sub)bands, of which 53 had prognostic value (35 bad, 18 good). Their prognostic value was summarized with a spike band score that delineated 23.8% of patients with a poor median overall survival (27.4 months versus not reached, P<0.001) using the training cohort of 206 patients. The spike band score was independent of other gene expression profiling-based risk scores, t(4;14), or del17p in an independent validation cohort of 345 patients.

CONCLUSIONS

We present a new approach to identify spike genes and their relationship to patients' survival.

摘要

背景

多发性骨髓瘤患者中常见遗传异常,这些异常可能使涉及肿瘤存活、增殖、代谢和耐药性的基因产物失活。特别是易位可能导致肿瘤细胞中靶向基因的高表达(称为尖峰表达)。我们在新诊断的多发性骨髓瘤患者的骨髓瘤细胞中鉴定了尖峰基因,并研究了它们的预后价值。

设计和方法

使用箱线图探针集信号分布和两个选择过滤器从多发性骨髓瘤细胞中挑选出具有尖峰表达的基因。

结果

在 206 例新诊断的多发性骨髓瘤患者队列中,鉴定出 2587 个具有尖峰表达的基因/表达序列标签。一些尖峰基因与一些转录因子(如 MAF 或 MMSET)和已知的复发性易位有关,这是意料之中的。尖峰基因与 DNA 拷贝数增加无关,并且对于大多数基因来说,它们涉及未知的机制。在尖峰基因中,36.7%显著聚类在 862 个记录的染色体(亚)带中的 149 个中,其中 53 个具有预后价值(35 个不良,18 个良好)。使用 206 例患者的训练队列,用尖峰带评分来总结它们的预后价值,该评分将 23.8%的患者划分为中位总生存期较差的患者(27.4 个月与未达到,P<0.001)。在 345 例独立验证队列中,尖峰带评分独立于其他基于基因表达谱的风险评分、t(4;14)或 del17p。

结论

我们提出了一种新的方法来鉴定尖峰基因及其与患者生存的关系。

相似文献

1
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.具有尖峰表达的基因在染色体(亚)带中聚集,并且尖峰(亚)带在多发性骨髓瘤患者中有很强的预后价值。
Haematologica. 2012 Apr;97(4):622-30. doi: 10.3324/haematol.2011.046821. Epub 2011 Nov 18.
2
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.从人类骨髓瘤细胞系的分子分类建立的多发性骨髓瘤患者高危特征。
Haematologica. 2011 Apr;96(4):574-82. doi: 10.3324/haematol.2010.033456. Epub 2010 Dec 20.
3
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.多发性骨髓瘤免疫球蛋白 λ 易位预示预后不良。
Nat Commun. 2019 Apr 23;10(1):1911. doi: 10.1038/s41467-019-09555-6.
4
The shaping and functional consequences of the dosage effect landscape in multiple myeloma.多发性骨髓瘤中剂量效应景观的形成及其功能后果。
BMC Genomics. 2013 Oct 2;14:672. doi: 10.1186/1471-2164-14-672.
5
Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.通过生物信息学分析鉴定骨髓瘤侧群细胞中的关键基因和通路。
Int J Med Sci. 2020 Jul 25;17(14):2063-2076. doi: 10.7150/ijms.48244. eCollection 2020.
6
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.16号染色体杂合性缺失的基因定位与表达分析确定WWOX和CYLD在决定多发性骨髓瘤的临床结局中起重要作用。
Blood. 2007 Nov 1;110(9):3291-300. doi: 10.1182/blood-2007-02-075069. Epub 2007 Jul 3.
7
Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.与MMSET骨髓瘤高度相关的基因对非MMSET骨髓瘤患者生存的影响。
Clin Cancer Res. 2016 Aug 15;22(16):4039-44. doi: 10.1158/1078-0432.CCR-15-2366. Epub 2016 Feb 4.
8
Gene expression profiling and multiple myeloma.基因表达谱分析与多发性骨髓瘤
Best Pract Res Clin Haematol. 2005;18(4):537-52. doi: 10.1016/j.beha.2005.02.003.
9
Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.位于染色体1q21带的CKS1B基因扩增和过表达与多发性骨髓瘤中p27Kip1水平降低及侵袭性临床病程相关。
Hematology. 2005;10 Suppl 1:117-26. doi: 10.1080/10245330512331390140.
10
MMSET: role and therapeutic opportunities in multiple myeloma.MMSET:在多发性骨髓瘤中的作用及治疗机会
Biomed Res Int. 2014;2014:636514. doi: 10.1155/2014/636514. Epub 2014 Jul 1.

引用本文的文献

1
Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.在多发性骨髓瘤中使用G-四链体稳定剂靶向转录-复制冲突。
Blood Neoplasia. 2025 Jan 20;2(2):100072. doi: 10.1016/j.bneo.2025.100072. eCollection 2025 May.
2
Immune escape of multiple myeloma cells results from low miR29b and the ensuing epigenetic silencing of proteasome genes.多发性骨髓瘤细胞的免疫逃逸源于miR29b水平低下以及随后蛋白酶体基因的表观遗传沉默。
Biomark Res. 2024 Apr 23;12(1):43. doi: 10.1186/s40364-024-00592-y.
3
Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma.获得性1号染色体拷贝数和结构变异的多组学图谱分析以鉴定多发性骨髓瘤的治疗弱点
Clin Cancer Res. 2023 Oct 2;29(19):3901-3913. doi: 10.1158/1078-0432.CCR-22-3209.
4
The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.BLM 解旋酶是多发性骨髓瘤中涉及复制应激存活和耐药性的新的治疗靶点。
Front Immunol. 2022 Dec 9;13:983181. doi: 10.3389/fimmu.2022.983181. eCollection 2022.
5
Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma.用于多发性骨髓瘤精准医学发展的多组学肿瘤分析技术。
Explor Target Antitumor Ther. 2021;2(1):65-106. doi: 10.37349/etat.2021.00034. Epub 2021 Feb 28.
6
Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.全面描绘多发性骨髓瘤的表观遗传学特征。
Theranostics. 2022 Jan 16;12(4):1715-1729. doi: 10.7150/thno.54453. eCollection 2022.
7
The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias.NADPH 氧化酶 NOX2 是急性髓系白血病化疗耐药相关的不良预后标志物。
Haematologica. 2022 Nov 1;107(11):2562-2575. doi: 10.3324/haematol.2021.279889.
8
RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma.基于RNA测序的转录组评分在多发性骨髓瘤中的预后及诊疗价值
J Pers Med. 2021 Sep 30;11(10):988. doi: 10.3390/jpm11100988.
9
Machine learning predicts treatment sensitivity in multiple myeloma based on molecular and clinical information coupled with drug response.机器学习基于分子和临床信息以及药物反应预测多发性骨髓瘤的治疗敏感性。
PLoS One. 2021 Jul 28;16(7):e0254596. doi: 10.1371/journal.pone.0254596. eCollection 2021.
10
G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.在多发性骨髓瘤中靶向 G9a/GLP 可促进自噬相关的细胞凋亡,并增强蛋白酶体抑制剂介导的细胞死亡。
Blood Adv. 2021 May 11;5(9):2325-2338. doi: 10.1182/bloodadvances.2020003217.

本文引用的文献

1
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.从人类骨髓瘤细胞系的分子分类建立的多发性骨髓瘤患者高危特征。
Haematologica. 2011 Apr;96(4):574-82. doi: 10.3324/haematol.2010.033456. Epub 2010 Dec 20.
2
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?易位 t(14;16)与多发性骨髓瘤:它真的是一个独立的预后因素吗?
Blood. 2011 Feb 10;117(6):2009-11. doi: 10.1182/blood-2010-07-295105. Epub 2010 Oct 20.
3
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.增殖是多发性骨髓瘤中独立的核心预后因素和个性化及风险适应性治疗的靶点。
Haematologica. 2011 Jan;96(1):87-95. doi: 10.3324/haematol.2010.030296. Epub 2010 Sep 30.
4
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.骨髓瘤相关染色体拷贝数异常及其预后价值概述。
Blood. 2010 Oct 14;116(15):e56-65. doi: 10.1182/blood-2010-04-279596. Epub 2010 Jul 8.
5
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.用于新诊断多发性骨髓瘤患者分子分类的基因表达谱分析。
Blood. 2010 Oct 7;116(14):2543-53. doi: 10.1182/blood-2009-12-261032. Epub 2010 Jun 23.
6
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.联合染色体异常 t(4;14)和 del(17p13)的信息与国际分期系统分类,可对接受自体干细胞移植的骨髓瘤患者进行分层。
Haematologica. 2010 Jul;95(7):1150-7. doi: 10.3324/haematol.2009.016436. Epub 2010 Mar 10.
7
A census of amplified and overexpressed human cancer genes.人类癌症基因扩增和过表达的普查。
Nat Rev Cancer. 2010 Jan;10(1):59-64. doi: 10.1038/nrc2771.
8
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.国际骨髓瘤工作组多发性骨髓瘤分子分类:重点综述。
Leukemia. 2009 Dec;23(12):2210-21. doi: 10.1038/leu.2009.174. Epub 2009 Oct 1.
9
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.骨形态发生蛋白6:一类由正常和恶性浆细胞表达的新型预后因子成员,可抑制增殖和血管生成。
Oncogene. 2009 Nov 5;28(44):3866-79. doi: 10.1038/onc.2009.257. Epub 2009 Aug 31.
10
Prognostic significance of copy-number alterations in multiple myeloma.多发性骨髓瘤中拷贝数改变的预后意义
J Clin Oncol. 2009 Sep 20;27(27):4585-90. doi: 10.1200/JCO.2008.20.6136. Epub 2009 Aug 17.